Antithrombotic Drugs: World Industry and Market Prospects 2015-2025

LONDON, May 1, 2015 /PRNewswire/ --

A new report by visiongain forecasts the overall world market for antithrombotic drugs will reach $22.4bn in 2019. That revenue forecast and others appear in Antithrombotic Drugs: World Industry and Market Prospects 2015-2025, published in March 2015.

The purpose of that investigation is to provide forecasts and qualitative analyses of the antithrombotic drugs market. Visiongain is a business information publisher and consultancy in London, UK. It produces analyses to help organisations understand potentials of industries and markets.

That new study analyses the antithrombotic drugs market in 2013 and 2014, as well as forecasting its prospects for revenue growth from 2015 to 2025. In particular, the work examines 14 leading products on the market in 2014, providing revenue forecasts for each as well as the overarching market and its segments.

Visiongain predicts the antithrombotic drugs market will recover from the sharp decline following patent expiries for Plavix and Lovenox in 2012. Although the market may not reach the same heights as it did in 2011 when Plavix revenue totalled $9.6bn, the patient population for antithrombotic drugs expands. The study finds the market will expand following its prior decline, until it faces patent expiries for other leading drugs in the second half of the forecasted period.

Alyscia Curtis, a pharmaceutical industry analyst in visiongain, said: "The world market for antithrombotic drugs generated $20.2bn in 2014. Although the loss of patent protection for Plavix and Lovenox has severely impacted the market, there is still potential for growth in the 2015-2025 period. The industry is changing, and novel anticoagulants are becoming the market leaders. The warfarin replacement market is large and with several compounds now vying for position. As antidotes become available for these novel anticoagulants, the market will grow. However, in the latter half of the forecast period, the antithrombotics market will decline as a result of patent expiries, generic competition and a limited pipeline. However, with a growing number of people suffering from cardiovascular diseases, and with aging populations, the antithrombotic drugs market retains promise for developments and revenue generation."

Visiongain's updated analysis shows revenue forecasts to 2025 at overall world market, submarket, product (brand) and national level. First it gives revenue predictions to 2025 for therapeutic submarkets at world level:

• Anticoagulants, also with sub-forecasts for direct factor Xa inhibitors, heparins, direct thrombin inhibitors and vitamin K antagonists
• Antiplatelet agents
• Fibrinolytics.

That study then predicts revenues of 14 leading drugs to 2025. Medicines forecasted and discussed include Plavix, Lovenox, Xarelto, Pradaxa, Activase, Effient, Aspirin Cardio and Pletal.

Research, data and analyses cover activities of Sanofi, Boehringer Ingelheim, Bayer, Johnson & Johnson, Genentech, The Medicines Company, Eli Lilly, Pfizer and other developers, manufacturers and marketers of antithrombotic drugs.

That new study also discusses R&D and commercial news, shows two research interviews and predicts revenues to 2025 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).

Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 adds to visiongain's analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.

For sample pages, and for further information about this report please visit https://www.visiongain.com/Report/1417/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2015-2025

For an executive summary please contact:
Email: Sara Peerun on [email protected]

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to [email protected]  or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first portofcall for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Companies Listed In This Company 

Abbott Laboratories
Ablynx
Aché
Accord Healthcare
Actavis Totowa
AdvanceCor GmbH
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
Apotex
App Pharmaceuticals
ARCA biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Laboratories (subsidiary of Barr Pharmaceuticals)
Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Capital TEN II
Canyon Pharmaceuticals
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica
Diakron Pharmaceuticals
Dr. Reddy's Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hercules Bioventures Partners
Hoechst Marion Roussell
Hospira
Hypermarcas
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Judicial Panel on Multidistrict Litigation (US)
Kowa
Kyowa Hakko Kirin
Lee's Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Macleods Pharmaceuticals
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mutual Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Roxane Laboratories
Sandoz
Sanofi
ScieGen Pharmaceuticals
Sun Pharmaceuticals Indusdtries
Takeda
Taro
Teva Pharmaceutical Industries
The Medicines Company
ThromboGenics
Tianjin Medical
Tobira Therapeutics
Torrent Pharmaceuticals
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
USL Pharma
Virginia Commonwealth University
Wockhardt
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila
Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain